Philippe Gallay Selected Research

Cyclophilins (Cyclophilin)

6/2021	Novel Cyclophilin Inhibitor Decreases Cell Proliferation and Tumor Growth in Models of Hepatocellular Carcinoma.
11/2019	Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis.
11/2019	A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.
1/2019	Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis.
2/2015	Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection.
7/2013	Curing a viral infection by targeting the host: the example of cyclophilin inhibitors.
10/2012	Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection.
7/2012	The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection.
8/2010	Cyclophilin inhibitors for the treatment of HCV infection.
3/2008	The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philippe Gallay Research Topics

Disease

8	Infections 01/2020 - 12/2007
4	Virus Diseases (Viral Diseases) 01/2020 - 11/2005
3	Neoplasms (Cancer) 06/2021 - 11/2019
3	Hepatocellular Carcinoma (Hepatoma) 06/2021 - 01/2019
3	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020 - 11/2019
2	Alcoholic Fatty Liver 01/2020 - 01/2019
2	HIV Infections (HIV Infection) 01/2020 - 08/2011
2	Liver Diseases (Liver Disease) 01/2020 - 11/2019
2	Hepatitis C 01/2020 - 03/2008
2	Fibrosis (Cirrhosis) 11/2019 - 01/2019
2	Chronic Hepatitis C 10/2012 - 07/2012
2	Dengue (Dengue Fever) 02/2012 - 01/2012
1	Pathologic Processes 11/2019
1	Non-alcoholic Fatty Liver Disease 11/2019
1	Inflammation (Inflammations) 01/2019
1	Body Weight (Weight, Body) 01/2019
1	Viremia 07/2012
1	Gonorrhea 10/2008
1	Coinfection 10/2008

Drug/Important Bio-Agent (IBA)

10	Cyclophilins (Cyclophilin)IBA 06/2021 - 03/2008
3	Antiviral Agents (Antivirals)IBA 01/2020 - 07/2012
2	CRV-431IBA 01/2020 - 11/2019
2	CollagenIBA 11/2019 - 01/2019
2	Anti-Infective Agents (Microbicides)IBA 01/2014 - 08/2011
1	Inhibitor of Apoptosis ProteinsIBA 01/2020
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2020
1	Programmed Cell Death 1 ReceptorIBA 01/2020
1	Protein Isoforms (Isoforms)IBA 11/2019
1	Carbon Tetrachloride (Tetrachloromethane)IBA 11/2019
1	Pharmaceutical PreparationsIBA 11/2019
1	IsomerasesIBA 11/2019
1	CytokinesIBA 01/2019
1	Blood Glucose (Blood Sugar)IBA 01/2019
1	SCY-635IBA 07/2012
1	InterferonsIBA 07/2012
1	6H- 6- imino- (2,3,4,5- tetrahydropyrimido)(1,2- c)- (1,3)benzothiazineIBA 02/2012
1	EnzymesIBA 01/2012
1	ImmunosorbentsIBA 01/2012
1	AntigensIBA 01/2012
1	AntibodiesIBA 01/2012
1	VaccinesIBA 01/2012
1	Capsid Proteins (Capsid Protein)IBA 01/2012
1	Tenofovir (Viread)FDA Link 08/2011
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2008
1	alisporivirIBA 03/2008
1	Syndecan-3IBA 12/2007
1	Antiviral Restriction FactorsIBA 11/2005

Therapy/Procedure

3	Therapeutics 10/2012 - 10/2008